

You asked:

1. Does your Health Board treat adult multiple myeloma [MM]? - if you refer your multiple myeloma patients to another centre, please state which.

Yes patients with multiple myeloma are treated in the health board.

2. If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following;

- **Bortezomib [Velcade] – 44**
- **Carfilzomib [Kyprolis] – 0**
- **Ixazomib [Ninlaro] – 8**
- **Lenalidomide [Revlimid] – 22**
- **Daratumumab [Darzalex] – 15**
- **Melphalan, prednisolone and thalidomide (known as MPT) – * Less than 5.**
- **Cyclophosphamide, thalidomide and dexamethasone (known as CTD) – 0**
- **Pomalidomide [Imnovid] – * Less than 5.**

3. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?

Nine.

If possible, how many CLL patients treated were new to therapy in the past 3 months?

* Less than 5.

4. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;

- **Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR) – * Less than 5**
- **Bendamustine and rituximab (known as BR) – * Less than 5**
- **Ibrutinib [Imbruvica] - 7**
- **Chlorambucil – * Less than 5**
- **Venetoclax – * Less than 5**
- **Obinutuzumab – 5**
- **Idelalisib – * Less than 5**
- **Fludarabine and rituximab (known as FR) – 0**
- **High-dose prednisone and rituximab – 0**
- **Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR) - 0**
- **Alemtuzumab (Campath) with rituximab – 0**

* Please note exact figures have been withheld due to the low numbers involved. This is due to the potential risk of identification if we released the number of patients for the specific year who have been admitted with this condition, which might then be linked with other information available in the public domain. Also,

responses under the Freedom of Information Act are made available to the public at large. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.